Clinical and biological significance of tissue transglutaminase in ovarian carcinoma

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5849-5858

  Jee, Young Hwang ^a,b   Mangala, Lingegowda S ^a   Fok, Jansina Y ^a   Lin, Yvonne G ^a   Merritt, William M ^a   Spannuth, Whitney A ^a   Nick, Alpa M ^a   Fiterman, Derek J ^a   Vivas Mejia, Pablo E ^a   Deavers, Michael T ^a   Coleman, Robert L ^a   Lopez Berestein, Gabriel ^a   Mehta, Kapil ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Dongguk University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DIOLEOYLPHOSPHATIDYLCHOLINE; DOCETAXEL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SMALL INTERFERING RNA; TISSUE TRANSGLUTAMINASE 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TISSUE TRANSGLUTAMINASE 2, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOMA; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; METABOLISM; MUTATION; OVARY TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; TRANSGLUTAMINASES;

EID: 48649099197     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6130     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Chandrashekar R, Tsuji N, Morales T, Ozols V, Mehta K. An ERp60-like protein from the filarial parasite Dirofilaria immitis has both transglutaminase and protein disulfide isomerase activity. Proc Natl Acad Sci U S A 1998;95:531-6.
4. Mehta K. Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 2005;38:1-18.
5. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534-9.
6. Lorand L, Graham RM. Transglutaminases: cross-linking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003;4:140-56.
7. Mishra S, Murphy LJ. Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 2004;279:23863-8.
8. 1B-adrenoreceptor-mediated GTP binding and intracellular calcium release. J Biol Chem 2001;276:5591-7.
9. Aeschlimann D, Thomazy V. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 2000;41:1-27.
10. Milakovic T, Tucholski J, McCoy E, Johnson GV. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 2004;279:8715-22.
11. Mishra S, Murphy LJ. The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 2006;339:726-30.
12. Mishra S, Saleh A, Espino PS, Davie JR, Murphy LJ. Phosphorylation of histones by tissue transglutaminase. J Biol Chem 2006;281:5532-8.
13. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFβ-dependent matrix deposition. J Cell Sci 2001;114:2989-3000.
14. Zemskov EA, Janiak A, Hang J, Waghray A, Belkin AM. The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 2006;11:1057-76.
15. Singh US, Pan J, Kao YL, Joshi S, Young KL, Baker KM. Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem 2003;278:391-9.
16. Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 2006;5:1493-503.
17. Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 2006;25:3049-58.
18. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007;26:2459-70.
19. Verma A, Wang H, Manavathi B, et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006;66:10525-33.
20. Landen CN, Jr., Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8.
21. Halder J, Kamat AA, Landen CN, Jr., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24.
22. Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004;165:1087-95.
23. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001;158:1279-88.
24. Chen JS, Agarwal N, Mehta K. Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat 2002;71:237-47.
25. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004;10:8068-76.
26. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006;5:1708-13.
27. 1 integrin supports survival of cells on fibronectin and upregulates Bcl-2 expression. Proc Natl Acad Sci U S A 1995;92:6161-5.
28. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 2003;63:2971-6.
29. Satpathy M, Cao L, Pincheira R, et al. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 2007;67:7194-202.
30. Fok JY, Mehta K. Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. Apoptosis 2007;12:1455-63.
31. Lee J, Kim YS, Choi DH, et al. Transglutaminase 2 induces nuclear factor-κB activation via a novel pathway in BV-2 microglia. J Biol Chem 2004;279:53725-35.
32. Mann AP, Verma A, Sethi G, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway. Cancer Res 2006;66:8788-95.
33. Kim DS, Park SS, Nam BH, Kim IH, Kim SY. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-κB inactivation. Cancer Res 2006;66:10936-43.
34. Dardik R, Inbal A. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 2006;312:2973-82.
35. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001;1540:1-21.
36. Stephens P, Grenard P, Aeschlimann P, et al. Cross-linking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci 2004;117:3389-403.
37. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 2005;4:33.
38. Molberg O, McAdam SN, Sollid LM. Role of tissue transglutaminase in celiac disease. J Pediatr Gastroenterol Nutr 2000;30:232-40.
39. Hoffner G, Djian P. Transglutaminase and diseases of the central nervous system. Front Biosci 2005;10:3078-92.
40. Bernassola F, Federici M, Corazzari M, et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient. FASEB J 2002;16:1371-8.
41. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1795-808.
42. Johnson TS, El-Koraie AF, Skill NJ, et al. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003;14:2052-62.
43. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 2007;115:232-45.
44. Yuan L, Siegel M, Choi K, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007;26:2563-73.